Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod versus fingolimod in pediatric relapsing-remitting multiple sclerosis
2020-004431-24Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Ponesimod arm with Fingolimod arm (2 arms). Primary endpoint: Time from randomization to first confirmed relapse. Started Aug 2022; status: active.
02
Drugs
ponesimodfingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2020-004431-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004431-24.